JankovicV1, Main, Exploration, bibRecordById, PMC:2031220

The impact of depressive symptoms in early Parkinson disease

Identifieur interne : 000E67 ( Main/Exploration ); précédent : 000E66; suivant : 000E68

The impact of depressive symptoms in early Parkinson disease

Auteurs : B Ravina [États-Unis] ; R Camicioli [Canada] ; P Como [États-Unis] ; L Marsh [États-Unis] ; J Jankovic [États-Unis] ; D Weintraub [États-Unis] ; J Elm [États-Unis]

Source :

Neurology [ 0028-3878 ] ; 2007.

RBID : Pascal:07-0388459

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Etat dépressif, Parkinson maladie.

English descriptors

KwdEn :
- Activities of Daily Living, Aged, Antidepressive Agents (therapeutic use), Antiparkinson Agents (adverse effects), Clinical Trials, Phase II as Topic (statistics & numerical data), Cohort Studies, Comorbidity, Depression, Depressive Disorder (diagnosis), Depressive Disorder (drug therapy), Depressive Disorder (epidemiology), Disability Evaluation, Double-Blind Method, Early Diagnosis, Female, Humans, Male, Mass Screening, Middle Aged, Motor Activity (drug effects), Motor Activity (physiology), Nervous system diseases, Neuropsychological Tests, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson disease, Predictive Value of Tests, Prevalence, Proportional Hazards Models, Randomized Controlled Trials as Topic (statistics & numerical data), Reproducibility of Results.
MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemical , therapeutic use : Antidepressive Agents.
- diagnosis : Depressive Disorder.
- drug effects : Motor Activity.
- drug therapy : Depressive Disorder, Parkinson Disease.
- epidemiology : Depressive Disorder, Parkinson Disease.
- physiology : Motor Activity.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- statistics & numerical data : Clinical Trials, Phase II as Topic, Randomized Controlled Trials as Topic.
- Activities of Daily Living, Aged, Cohort Studies, Comorbidity, Disability Evaluation, Double-Blind Method, Early Diagnosis, Female, Humans, Male, Mass Screening, Middle Aged, Neuropsychological Tests, Predictive Value of Tests, Prevalence, Proportional Hazards Models, Reproducibility of Results.

Abstract

Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD. Methods: We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD. Results: A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% Cl 1.29, 2.68). Conclusions: Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2031220

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The impact of depressive symptoms in early Parkinson disease</title>
<author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B" last="Ravina">B Ravina</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology University of Rochester School of Medicine and Dentistry</s1>
<s2>NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Camicioli, R" sort="Camicioli, R" uniqKey="Camicioli R" first="R" last="Camicioli">R Camicioli</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Department of Neurology University of Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P" last="Como">P Como</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology University of Rochester School of Medicine and Dentistry</s1>
<s2>NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L" last="Marsh">L Marsh</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology Baylor University</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D" last="Weintraub">D Weintraub</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Departments of Psychiatry and Neurology University of Pennsylvania</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Departments of Psychiatry and Neurology University of Pennsylvania</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elm, J" sort="Elm, J" uniqKey="Elm J" first="J" last="Elm">J Elm</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Biostatistics Medical University of South Carolina</s1>
<s2>Charleston</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Department of Biostatistics Medical University of South Carolina</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0388459</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0388459 INIST</idno>
<idno type="RBID">Pascal:07-0388459</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000058</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000108</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000052</idno>
<idno type="wicri:doubleKey">0028-3878:2007:Ravina B:the:impact:of</idno>
<idno type="wicri:Area/Main/Merge">000E94</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2031220</idno>
<idno type="RBID">PMC:2031220</idno>
<idno type="wicri:Area/Pmc/Corpus">000240</idno>
<idno type="wicri:Area/Pmc/Curation">000240</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000239</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000158</idno>
<idno type="wicri:Area/PubMed/Curation">000158</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000153</idno>
<idno type="wicri:Area/Ncbi/Merge">000149</idno>
<idno type="wicri:Area/Ncbi/Curation">000149</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000149</idno>
<idno type="wicri:doubleKey">0028-3878:2007:Ravina B:the:impact:of</idno>
<idno type="wicri:Area/Main/Merge">000D55</idno>
<idno type="wicri:Area/Main/Curation">000E67</idno>
<idno type="wicri:Area/Main/Exploration">000E67</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The impact of depressive symptoms in early Parkinson disease</title>
<author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B" last="Ravina">B Ravina</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology University of Rochester School of Medicine and Dentistry</s1>
<s2>NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Camicioli, R" sort="Camicioli, R" uniqKey="Camicioli R" first="R" last="Camicioli">R Camicioli</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Department of Neurology University of Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P" last="Como">P Como</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology University of Rochester School of Medicine and Dentistry</s1>
<s2>NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L" last="Marsh">L Marsh</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology Baylor University</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D" last="Weintraub">D Weintraub</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Departments of Psychiatry and Neurology University of Pennsylvania</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Departments of Psychiatry and Neurology University of Pennsylvania</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elm, J" sort="Elm, J" uniqKey="Elm J" first="J" last="Elm">J Elm</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Biostatistics Medical University of South Carolina</s1>
<s2>Charleston</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Department of Biostatistics Medical University of South Carolina</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Antidepressive Agents (therapeutic use)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Clinical Trials, Phase II as Topic (statistics & numerical data)</term>
<term>Cohort Studies</term>
<term>Comorbidity</term>
<term>Depression</term>
<term>Depressive Disorder (diagnosis)</term>
<term>Depressive Disorder (drug therapy)</term>
<term>Depressive Disorder (epidemiology)</term>
<term>Disability Evaluation</term>
<term>Double-Blind Method</term>
<term>Early Diagnosis</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mass Screening</term>
<term>Middle Aged</term>
<term>Motor Activity (drug effects)</term>
<term>Motor Activity (physiology)</term>
<term>Nervous system diseases</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Predictive Value of Tests</term>
<term>Prevalence</term>
<term>Proportional Hazards Models</term>
<term>Randomized Controlled Trials as Topic (statistics & numerical data)</term>
<term>Reproducibility of Results</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Clinical Trials, Phase II as Topic</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Cohort Studies</term>
<term>Comorbidity</term>
<term>Disability Evaluation</term>
<term>Double-Blind Method</term>
<term>Early Diagnosis</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mass Screening</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Predictive Value of Tests</term>
<term>Prevalence</term>
<term>Proportional Hazards Models</term>
<term>Reproducibility of Results</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Etat dépressif</term>
<term>Parkinson maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD. Methods: We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD. Results: A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% Cl 1.29, 2.68). Conclusions: Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Texas</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B" last="Ravina">B Ravina</name>
</region>
<name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P" last="Como">P Como</name>
<name sortKey="Elm, J" sort="Elm, J" uniqKey="Elm J" first="J" last="Elm">J Elm</name>
<name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
<name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L" last="Marsh">L Marsh</name>
<name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D" last="Weintraub">D Weintraub</name>
</country>
<country name="Canada"><noRegion><name sortKey="Camicioli, R" sort="Camicioli, R" uniqKey="Camicioli R" first="R" last="Camicioli">R Camicioli</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E67 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E67 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:07-0388459
   |texte=   The impact of depressive symptoms in early Parkinson disease
}}

This area was generated with Dilib version V0.6.19.
Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024

Serveur d'exploration autour de Joseph Jankovic

The impact of depressive symptoms in early Parkinson disease

The impact of depressive symptoms in early Parkinson disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration autour de Joseph Jankovic
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.